Arca
Skip to content
Tools
Tools

AXL: Tyrosine-protein kinase receptor UFO

Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding growth factor GAS6 and which is thus regulating many physiological processes including cell survival, cell proliferation, migration and differentiation.

  • Drugs that act on it: 6
  • Approved: 1
  • In phases 1 to 3: 5
  • Sponsors: 4

Who is on it, and how far along

Every drug ChEMBL records acting on AXL, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 3
  • Antibody-drug conjugate 2
  • Other 1

Approved1

  • Gilteritinib

Phase 30

    Phase 24

    • Bemcentinib
    • Enapotamab vedotin
    • Mecbotamab vedotin
    • Ningetinib

    Phase 11

    • BPI-9016

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • BerGenBio ASA117%
    • Betta Pharmaceuticals Co., Ltd.117%
    • Jiangsu Alphamab Biopharmaceuticals Co., Ltd117%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 4 of 6 act as: Tyrosine-protein kinase receptor UFO inhibitor; the rest name their own mechanism.
    GilteritinibBoxed warningApprovedAstellas PharmaSmall moleculeInhibitor43
    BemcentinibPhase 2BerGenBio ASASmall moleculeInhibitor2
    Enapotamab vedotinPhase 2—Antibody-drug conjugateBinding agentTyrosine-protein kinase receptor UFO binding agent0
    Mecbotamab vedotinPhase 2—Antibody-drug conjugateBinding agentTyrosine-protein kinase receptor UFO binding agent0
    NingetinibPhase 2Jiangsu Alphamab Biopharmaceuticals Co., LtdSmall moleculeInhibitor0
    BPI-9016Phase 1Betta Pharmaceuticals Co., Ltd.OtherInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 10 in all, from ClinicalTrials.gov.
    Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory LeukemiaGilteritinibPhase 2Not yet recruitingFlorian KuchenbauerAug 10, 2026
    DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AMLGilteritinibPhase 3RecruitingThe Second Affiliated Hospital of Kunming Medical UniversityJul 20, 2026
    Study of SA+X in the Treatment of Newly Diagnosed AMLGilteritinibPhase 2RecruitingRuijin HospitalApr 23, 2026
    Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell CarcinomaBemcentinibPhase 2 / Phase 3Not yet recruitingShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityApr 17, 2026
    MRD-guided Maintenance Post-HCT: Gilteritini vs SorafenibGilteritinibPhase 3RecruitingThe First Affiliated Hospital of Soochow UniversityMar 11, 2026
    Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell CarcinomaBemcentinibPhase 3RecruitingShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityMar 3, 2026
    FLT3-ITD Targeted Therapy in Fit AML PatientsGilteritinibPhase 2 / Phase 3Not yet recruitingEuropean Organisation for Research and Treatment of Cancer - EORTCFeb 23, 2026
    VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AMLGilteritinibPhase 3Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, ChinaFeb 12, 2026
    Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AMLGilteritinibPhase 2RecruitingFirst Affiliated Hospital of Zhejiang UniversityDec 2, 2025
    A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)GilteritinibPhase 1RecruitingAstellas Pharma Global Development, Inc.Aug 24, 2025

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    Neurodegenerative disease
    0.57
    Alzheimer disease
    0.54
    Parkinson disease
    0.53
    Lysosomal storage disease
    0.53
    Dengue disease
    0.51
    Neoplasm
    0.41
    Acute myeloid leukemia by FAB classification
    0.38
    Head and neck squamous cell carcinoma
    0.33
    NK-cell enteropathy
    0.26

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4895, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P30530, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.